340 related articles for article (PubMed ID: 34516636)
1. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G; Bataller A; Garrido A; Hoyos M; Arnan M; Vives S; Coll R; Tormo M; Sampol A; Escoda L; Salamero O; Garcia A; Bargay J; Aljarilla A; Nomdedeu JF; Esteve J; Sierra J; Pratcorona M
Blood Adv; 2022 Feb; 6(3):882-890. PubMed ID: 34516636
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of
Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
9. The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Heiblig M; Duployez N; Marceau A; Lebon D; Goursaud L; Plantier I; Stalnikiewich L; Cambier N; Balsat M; Fossard G; Labussière-Wallet H; Barraco F; Ducastelle-Lepretre S; Sujobert P; Huet S; Hayette S; Ghesquières H; Thomas X; Preudhomme C
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33947035
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
[TBL] [Abstract][Full Text] [Related]
11. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
15. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
16. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract][Full Text] [Related]
19. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
20. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
